Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 10-15

  D'Amico, Anthony V ^a   Chen, Ming Hui ^b   Renshaw, Andrew A ^a   Loffredo, Marian ^a   Kantoff, Philip W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Prostate cancer; Radiotherapy; Testosterone

Indexed keywords

COMORBIDITY; CONFIDENCE INTERVAL; COX REGRESSION ANALYSIS; HAZARD RATIO; HORMONAL THERAPY; PROGNOSTIC FACTORS; PROSTATE CANCER; PROSTATE CANCERS; TESTOSTERONE;

EPIDEMIOLOGY; MARINE RISERS; RADIOTHERAPY; REGRESSION ANALYSIS; RISK ANALYSIS;

RISK MANAGEMENT;

FLUTAMIDE; GONADORELIN AGONIST; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CAUSE OF DEATH; COMORBIDITY; CONFIDENCE INTERVALS; FLUTAMIDE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REGRESSION ANALYSIS; RISK ASSESSMENT; TESTOSTERONE; TIME FACTORS;

EID: 68649095420     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.082     Document Type: Article

References (26)

1. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression therapy and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 360 (2002) 103-108
2. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 2497-2504
3. Denham J., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96-01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
4. D'Amico A.V., Chen M., Renshaw A.A., et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299 (2008) 289-295
5. D'Amico A.V., Renshaw A.A., Loffredo M., et al. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer 110 (2007) 1723-1728
6. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on randomized phase III clinical trials using limited hormonal therapy. J Urol 173 (2005) 1567-1571
7. Oefelein M.G. Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: A phase I assessment. Urology 54 (1999) 694-699
8. Kaku H., Saika T., Tsushima T., et al. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 66 (2006) 439-444
9. Bong G.W., Clarke Jr. H.S., Hancock W.C., et al. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing agonist in patients with prostate cancer. Urology 71 (2008) 1177-1180
10. Piccirillo J.F., Tierney R.M., Costas I., et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291 (2004) 2441-2447
11. Beahrs O.H., Henson D.E., Hunter R.V.P., and American Joint Committee on Cancer. Manual for staging cancer. 4th ed. (1992), JB Lippincott, Philadelphia
12. In: Agresti A. (Ed). An introduction to categorical data analysis. 2nd ed (2002), John Wiley & Sons, New York 16-52
13. In: Hollander M., Douglas A., and Wolfee D.A. (Eds). Nonparametric statistical methods. 2nd ed (1999), John Wiley & Sons, New York 189-269
14. Klein J.P., and Moeschberger M.L. Semiparametric proportional hazards regression with fixed covariates. In: Klein J.P., and Moeschberger M.L. (Eds). Survival analysis: techniques for censored and truncated data. 2nd ed (2003), Springer, New York 243-293
15. Klein J.P., and Moeschberger M.L. Refinements of the semiparametric proportional hazards model. In: Klein J.P., and Moeschberger M.L. (Eds). Survival analysis: techniques for censored and truncated data. 2nd ed (2003), Springer, New York 295-328
16. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
17. Kaplan E.L., and Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-500
18. Gaynor J.J., Feuer E.J., Tan C.C., et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88 (1993) 400-409
19. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
20. In: Neter J., Wassermann W., and Kutner M. (Eds). Simultaneous inferences and other topics in regression analyses-1. In: applied linear regression models (1983), Richard D Irwin, Homewood, IL 150-153
21. Bolla M., van Tienhoven G., de Reijke T.M., et al., EORTC Radiation Oncology and Genito-Urinary Tract Cancer Groups. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC phase III trial 22961. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25 Suppl (2007) 18S
22. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 29 (2005) 238-244
23. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
24. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-tern androgen deprivation therapy. J Clin Oncol 24 (2006) 3979-3983
25. D'Amico A.V., Denham J.W., Crook J., et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25 (2007) 2420-2425
26. Camara C., Dall'Oglio M.F., Alexana C., et al. High prevalence of metabolic syndrome in patients undergoing long-term hormonal therapy for prostate cancer-A preliminary report. AUA Annual Meeting Proceedings. J Urol 179 Suppl (2007) 401